CORAL GABLES, FL / ACCESSWIRE / March 15, 2019 / The future successes of the healthcare stock market are intrinsically entwined with whether, or not, healthcare companies are aptly prepared to rise to the challenge of taking care of the world's population. Consumers both depend on and expect healthcare companies to invest and innovate to create top-line care options and treatments to improve their health and quality of life. Considering the sheer amount of capital flowing into the healthcare sector, potential investors looking for opportunities could benefit from looking into healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Soleno Therapeutics Inc (SLNO), Achieve Life Sciences Inc (ACHV), and Conformis Inc (CFMS) are 4 healthcare companies heating things up on Friday.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care. At a time where consumers depend on healthcare companies to provide qualitative care solutions, Premier Health is prepared to meet the needs of its patients.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) dominated headlines earlier this week when the Company announced that it is working with Bio Conscious Technologies to bring their artificial intelligence technology to Premier Health's active patient network. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.
Following the announcement, Dr. Essam Hamza, CEO of Premier Health Group (OTC:PHGRF) (CSE:PHGI), commented, ''since the beginning, remote patient monitoring has been an integral component of our telemedicine app. DiaBits will enable our diabetic patients to dramatically increase glucose control and improve their quality of life. We are eager to work with the team at BCT to bring this innovative solution to our comprehensive telemedicine app.''
Soleno Therapeutics Inc (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, yesterday announced that the Data Safety Monitoring Board has recommended the continuation of the Company's Phase III trial in Prader-Willi Syndrome patients, DESTINY PWS, without any changes. In response to the news, the Company's shares soared 222.22% in the market on Friday.
Dr. Anish Bhatnagar, CEO of Soleno, said, ''we are delighted with the DSMB's positive recommendation to continue the Phase III trial as planned as it further supports DCCR's safety profile. We are continuing to enroll patients with 14 sites activated in DESTINY PWS. In addition, patients continue to roll over into C602, the 9-month open-label safety extension study for patients completing blinded treatment in the DESTINY PWS study.''
Achieve Life Sciences Inc (ACHV) saw impressive gains in the market on Friday, with its shares up 35.51%, trading at $3.32 per share early in the afternoon. Their share performance may be connected to the Company's announcement from earlier this week which provided an update on the cytisinicline clinical development program.
Rick Stewart, Chairman, and CEO of Achieve Life Sciences stated, ''the cytisinicline development program continues to advance rapidly and we are well-poised for continued success in 2019. As demonstrated by the swift enrollment in our Phase 2b trial, new treatments are desperately needed to help the millions of people who desire to quit smoking.''
Conformis Inc (CFMS), a medical technology company that uses its proprietary iFit image-to-Implant technology platform to develop, manufacture, and sell joint replacement implants, announced earlier this week that the Company will be featuring the new 3D designed Conformis Hip System as a key technology focus at the 2019 American Academy of Orthopedic Surgeons annual conference March 13-15, 2019 in Las Vegas, NV.
Following the announcement, Mark Augusti, President, and CEO of Conformis said, ''at the Conformis product booth we will give an overview of the design rationale as well as a hands-on demonstration of our CAD design process and explanation of the hip iView pre-surgical plan. Surgeons will be able to have in-depth conversations with engineers to understand the design rationale and process as well as speak directly to members of our MAB to hear first-hand how this new technology is providing greater insight into patient anatomy and care through the surgical planning process.''
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 CASH for & were paid ''500,000'' shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: